Latest by Bristol-Myers Squibb Company and Gilead Sciences, Inc.

Promo Image

Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce

New York, NY and Foster City, CA -- Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced they have obtained data supporting bioequivalence of a new formulation of the fixed-dose combination of Bristol-Myer...